BioXcel enters retention bonus agreements with key employees, CEO gets $650K after sNDA submission

BioXcel Therapeutics, Inc.

CEO receives $650K bonus ($325K initial, $325K final); other key employees get $225K ($150K initial, $75K final).
Final payment due April 15, 2026, contingent on continued employment and no default under Oaktree credit agreement.
Final payment accelerates if company raises $25M+ capital or a change of control occurs before April 15, 2026.
Employees must repay bonuses if terminated for cause or resign without good reason before Dec 31, 2026 (or Sep 30, 2026 if only initial paid).
Agreements follow submission of sNDA for IGALMI for acute agitation in bipolar disorder or schizophrenia in outpatient setting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.